|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||23.86 - 24.22|
|52 Week Range||21.25 - 30.25|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.95 (8.30%)|
|Ex-Dividend Date||Oct 21, 2022|
|1y Target Est||N/A|
BOSTON, November 30, 2022--The Eaton Vance closed-end funds listed below released today the estimated sources of their November distributions (each a "Fund"). This press release is issued as required by the Funds’ managed distribution plan (Plan) and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly, as noted below, cash distributions to common shareholders, stated in terms of a fixed am
The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021. In contrast to previously nominated programmes, which are small molecule based, the newly designated project utilises an antisense-based approach.
HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.